<DOC>
	<DOCNO>NCT00702884</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib work treat patient relapsed refractory esophageal gastroesophageal junction cancer .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Relapsed Refractory Esophageal Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine progression-free survival rate ( complete response , partial response , stable disease define RECIST criterion [ Response Evaluation Criteria solid Tumors ] ) 24 week patient relapse refractory esophageal gastroesophageal junction cancer treat sunitinib malate . Secondary - To explore predictive role hybrid image protocol combine PET/CT ( Positron emission tomography ) scan simultaneously dynamic contrast-enhanced MRI . - Correlate quantitative change mean vessel density , alteration tumor cell proliferation , apoptosis tumor biopsy specimens clinical outcome patient . - To evaluate objective response define RECIST criterion , median overall survival , median progression-free survival patient . - To evaluate toxicity sunitinib malate patient . OUTLINE : Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood tumor tissue sample collection periodically correlative laboratory study . Tumor tissue sample assess immunohistochemistry TUNEL detection quantitation mean vessel density , proliferate tumor cell , apoptosis . Tumor tissue sample also assess immunohistochemistry MAPK level . Blood sample analyze ELISA VEGF , PlGF , sVEGFR2 , sVEGFR3 level . Patients also undergo PET/CT scan dynamic contrast-enhanced MRI periodically correlative study . After completion study treatment , patient follow least 6 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal gastroesophageal junction carcinoma amenable curative surgery curative therapy Advanced , relapse refractory disease Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : ECOG ( Eastern Cooperative Oncology Group ) performance status 01 Life expectancy &gt; 12 week WBC ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Serum calcium ≤ 12.0 mg/dL Total bilirubin normal AST ( aspartate aminotransferase ) ALT ( Alanine Aminotransferase ) ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior , , 28 day completion study treatment No history allergic reaction attribute compound similar chemical biologic composition sunitinib malate No ongoing cardiac dysrhythmias ≥ grade 2 , atrial fibrillation grade , prolongation QTc ( correct QT interval ) interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) No hypertension control medication ( i.e. , systolic/diastolic blood pressure &gt; 150/100 mm Hg despite optimal medical therapy ) No myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within past 12 month No cerebrovascular accident transient ischemic attack within past 12 month No pulmonary embolism within past 12 month No condition would impair ability swallow retain sunitinib malate tablet ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day No serious nonhealing wound , ulcer , bone fracture No preexisting thyroid abnormality maintain normal range medication No concurrent uncontrolled illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : Recovered prior therapy At least 4 week since prior radiotherapy major surgery At least 4 week since prior chemotherapy ( 6 week mitomycin C , carmustine , alkylating agent ) No 6 prior course alkylating agent No 450 mg/m² prior doxorubicin hydrochloride 900 mg/m² prior epirubicin hydrochloride No 2 line prior therapy metastatic setting No prior antiVEGF monoclonal antibody , bevacizumab aflibercept No prior tyrosine kinase inhibitor similar target ( e.g. , sorafenib tosylate axitinib ) No concurrent investigational agent No concurrent therapeutic dos coumarinderivative anticoagulant , warfarin Warfarin dose ≤ 2 mg daily allow prophylaxis thrombosis Low molecular weight heparin allow provide PT/INR ( Prothrombin time international normalized ratio ) ≤ 1.5 No concurrent combination antiretroviral therapy HIVpositive patient No concurrent agent proarrhythmic potential ( e.g. , terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>